Boston Scientific Again Trims FY26 Outlook - Update

rttnews.com · 2026-10-28

While reporting financial results for the third quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) provided its adjusted earnings and sales growth guidance for the fourth quarter, and trimmed its full-year 2026 outlook.

TickrTrends take: Boston Scientific's latest reduction to its FY26 guidance suggests the company is facing near-term headwinds that warrant monitoring by value investors, particularly given the stock's current undervalued classification on TickrTrends. A pattern of trimmed outlooks can test whether the underlying business fundamentals justify the discount valuation, making it important to track whether future quarters show stabilization or continued pressure. For those evaluating BSX within the Healthcare sector, the key consideration is whether these guidance cuts represent temporary operational challenges or signal a more persistent shift in the company's growth trajectory.

Read the full story at rttnews.com →